Evidence map›Paper›PMID 40340694›Full record

ArticleBMC public health2025

Getting to full disclosure: HCV testing and status disclosure behaviors among PWID and their injecting partners.

Maia Scarpetta, Rachel Kanner, Neia Prata Menezes, Claire C McDonell, Julie Bruneau, Kimberly Page, Meghan D Morris

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maia Scarpetta *Department of Epidemiology and Biostatistics, University of California, San Francisco, Box 1224, San Francisco, CA, 550 16thStreet94158, USA.
Rachel Kanner *Department of Medicine, University of California San Francisco, San Francisco, USA.
Neia Prata MenezesCenter for AIDS Prevention Sciences (CAPS), University of California, San Francisco, San Francisco, USA.
Claire C McDonellDepartment of Epidemiology and Biostatistics, University of California, San Francisco, Box 1224, San Francisco, CA, 550 16thStreet94158, USA.
Julie BruneauDepartment of Family Medicine and Emergency Medicine, Université de Montréal, Montréal, Canada.
Kimberly PageDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Meghan D MorrisDepartment of Epidemiology and Biostatistics, University of California, San Francisco, Box 1224, San Francisco, CA, 550 16thStreet94158, USA. Meghan.Morris@ucsf.edu.

Funding

The Impact of Stigma on Interpersonal Relationships of Young Adult People who Inject DrugsR01DA053325 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Meghan D Morris · 2022 to 2026
$3.7M
Understanding the interpersonal context of HIV/HCV risk within injecting dyadsK01DA037802 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORRIS, MEGHAN D · 2014 to 2018
$913k
Harnessing interpersonal connections for improved patient-oriented research for people who inject drugs (PWID)K24DA061103 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Meghan D Morris · 2025 to 2026
$433k
CIHR MOP135260Fonds de recherche du Québec FRSQ5227NIDA NIH HHS K01 DA037802NIDA NIH HHS K01DA037802NIDA NIH HHS K24 DA061103NIDA NIH HHS R01DA053325NIDA NIH HHS R01DA16017NIDA NIH HHS T32MH19105
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) face a substantial risk of hepatitis C virus (HCV) infection, often in the context of multiple injecting partnerships. The disclosure of HCV status to injecting partners holds significant implications for prevention and care among PWID.

methodsWe used cross-sectional dyadic survey data (collected from both members of injecting partnerships) to estimate the prevalence of HCV-status disclosure between PWID and their injecting partners, overall and by partnership HCV infection status.

resultsAcross the two study sites (San Francisco and Montreal), 91% of participants self-reported receiving an HCV test, resulting in 162 individuals and 131 partnerships. A majority (57%) self-reported being HCV positive. HCV status disclosure was prevalent overall (79%) and was most common (41%) with partnerships where both partners' status was positive (+ / +) but less common (17%) when one partner was positive ( ±) and when neither partner was positive (-/-) (32%); no disclosure was more common when both partners were negative (-/-) (50%).

conclusionsOverall, our study demonstrated a high prevalence of HCV testing and subsequent disclosure of HCV status within injecting partnerships. This presents an opportunity to leverage these relationships for treatment linkage and prevention messaging.

Indexed as

DisclosureHepatitis CSelf DisclosureSexual PartnersSubstance Abuse, IntravenousTruth DisclosureAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedQuebecSan FranciscoYoung AdultHCV disclosureHCV testingHepatitis C virusInjecting partnershipsPeople who inject drugs

Identifiers

PMID40340694
PMCPMC12060384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.